Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 2, 2008, Pages 144-148

  Saif, M Wasif ^a,b   Longo, Walter L ^a   Israel, Gary ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Medical Oncology   (United States)

Author keywords

Cetuximab; Epidermal growth factor receptor; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB;

ABSCESS; ADULT; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; NAIL DISEASE; NAUSEA; NEUROPATHY; RASH; SEPSIS; SKIN FISSURE; TREATMENT RESPONSE;

EID: 42049112958     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.020     Document Type: Article

References (18)

1. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004; 350:2335-42.
3. Hochster HS, Welles L, Hart L et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized "TREE-2" trial. Presented at: the 2005 American Society of Clinical Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 241.
4. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at: the 2005 American Society of Clinical Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 169a.
5. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-61.
6. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006; 5:553-66.
7. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-50.
8. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials: referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 2001; 15:1019-26.
9. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002; 29(suppl 11):29-37.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
11. Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006; 17:1227-9.
12. Azim HA, Jr, Ganti AK. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand? Cancer Treat Rev 2006; 32:630-6.
13. Motl, S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 2005; 62:1241.
14. Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 20:1892-7
15. Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:118-24.
16. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6:175-82.
17. Leo S, Tatulli C, Taveri R, et al. Dermatological toxicity from chemotherapy containing 5-fluorouracil. J Chemother 1994; 6:423-6.
18. Ratain MJ, Eisen T, Stadler WM, et al. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2006; 24:2505-12.